Erratum: Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between the NPM leukemic mutant and NF-B in AML carrying NPM1 mutations(Leukemia (2008) 22 (1234-1240) DOI: 10.1038/leu.2008.68);Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations

Leukemia

Volumn 22, Issue 6, 2008, Pages 1234-1240

  Cilloni, D ^a   Messa, F ^a   Rosso, V ^a   Arruga, F ^a   Defilippi, I ^a   Carturan, S ^a   Catalano, R ^a   Pautasso, M ^a   Panuzzo, C ^a   Nicoli, P ^a   Messa, E ^a   Morotti, A ^a   Iacobucci, I ^b   Martinelli, G ^b   Bracco, E ^a   Saglio, G ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; NUCLEOPHOSMIN; NUCLEOPHOSMIN 1;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTANT; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

EID: 45149088440     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.64     Document Type: Erratum

References (30)

1. den Besten W, Kuo ML, Williams RT, Sherr CJ. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 2005; 4: 1593-1598.
2. Cheng K, Grisendi S, Clohessy JG, Majid S, Bernardi R, Sportoletti P et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene 2007; 22: 7391-7400.
3. Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L et al Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res 15; 66: 3044-3050.
4. Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R, Marine JC et al. Nucleophosmin is required for DNA integrity and p19 Arf protein stability. Mol Cell Biol 2005; 25: 8874-8886.
5. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
6. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87: 882-886.
7. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukaemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12: 265-275.
8. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 332: 254-266.
9. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733-3739.
10. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747-3754.
11. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106: 3740-3746.
12. Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106: 2854-2861.
13. Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007; 110: 979-985.
14. Ghosh S, Karin M. Missing pieces in the NF-kB puzzle. Cell 2002; 109: 81-96.
15. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NF-kB/ Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 2003; 18: 1-7.
16. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
17. Garg A, Aggarwal BB. Nuclear transcription factor-kB as a target for cancer drug development. Leukemia 2002; 16: 1053-1068.
18. Senftleben U, Karin M. The IKK/NF-kB pathway. Crit Care Med 2002; 30: 18-26.
19. Dhar SK, Lynn BC, Daosukho C, St Clair DK. Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene. J Biol Chem 2004; 279: 28209-28219.
20. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
21. Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, Macleod RA et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005; 19: 1760-1767.
22. Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E et al The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance. Leukemia 2007; 20: 61-67.
23. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): Biologic and clinical features. Blood 2007; 109: 874-885.
24. Aggarwall BB. Nuclear factor-kappaB: The enemy within cancer. Cancer Cell 2004; 6: 203-208.
25. Takebayashi T, Higashi H, Sudo H, Ozawa H, Suzuki E, Shirado O et al NF-kappaB-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor derived pRB mutants. J Biol Chem 2003; 278: 14897-14905.
26. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
27. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: A treasure trove for drug development. Nat Rev 2004; 3: 17-26.
28. Frelin C, Imbert V, Griessinger E. Peyron AC, Rochet N. Philip P et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2 induced apoptosis of human acute myeloid leukaemia cells. Blood 2005; 105: 804-811.
29. Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor kappakappaB as a target for new drug development in myeloid malignancies. Haematologica 2007; 92: 1224-1229.
30. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: A novel class of potent and effective anti-tumor agents. Cancer Res 1999; 59: 2615-2622.